Evidence map›Paper›PMID 35326345›Full record

ReviewBrain sciences2022

Gender Differences in Dual Diagnoses Associated with Cannabis Use: A Review.

Laura Prieto-Arenas, Ignacio Díaz, M Carmen Arenas

Open access · goldAbstract readReview
In one paragraph

Review in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Laura Prieto-ArenasFacultad de Medicina, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain.
Ignacio DíazFacultad de Medicina, Universidad Católica de Valencia San Vicente Mártir, 46001 Valencia, Spain.
M Carmen ArenasFacultad de Psicología y Logopedia, Universitat de València, 46010 Valencia, Spain.ORCID 0000-0003-2201-6882
Valencia Catholic University Saint Vincent Martyr · ESUniversitat de València · ES

Funding

Ministerio de Ciencia, Innovación y Universidades, Spain RD21/0009/0005University of Valencia UV-INV-AE-1551472
6 · The paper itself

Abstract

Gender differences in psychiatric disorders and drug use are well known. Cannabis is the most widely used illegal drug among young people. In recent years, its use has been related to the development of psychiatric pathologies; however, few studies have incorporated the gender perspective as of yet. The present work analyses the literature to determine the existence of gender differences in the development of psychotic, depressive and anxious symptoms associated with cannabis use. First, we describe cannabis misuse and its consequences, paying special attention to adolescent subjects. Second, the main gender differences in psychiatric disorders, such as psychosis, depression, anxiety and cannabis use disorders, are enumerated. Subsequently, we discuss the studies that have evaluated gender differences in the association between cannabis use and the appearance of psychotic, depressive and anxious symptoms; moreover, we consider the possible explanations for the identified gender differences. In conclusion, the studies referred to in this review reveal the existence of gender differences in psychiatric symptoms associated with cannabis use, although the direction of such differences is not always clear. Future research is necessary to discern the causal relationship between cannabis use and the development of psychiatric symptoms, as well as the gender differences found.

Indexed as

anxietycannabisdepressionfemalegender differenceshumansmalepsychotic disorders

Identifiers

PMID35326345
PMCPMC8946108
OpenAlexW4221123572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.